Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022

/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the...

Related Keywords

France ,Germany ,Salt Lake City ,Utah ,United States ,United Kingdom ,Italy ,Montreal ,Quebec ,Canada ,Toronto ,Ontario ,Spain ,Chris Gibson ,Shafique Virani ,Niloy Jewel Samadder ,Office Of Individualized Precision Medicine ,Enterprise Co ,European Commission ,Drug Administration ,Mayo Clinic Comprehensive Cancer Center ,Familial Adenomatous Polyposis ,Fast Track ,Orphan Drug ,Mayo Clinic ,Enterprise Co Director ,Precision Medicine ,Mayo Clinic Comprehensive Cancer ,Clostridium Difficile Infection ,Chief Business Officer ,Interim Chief Medical Officer ,San Francisco Bay ,Recursion ,